Navigation Links
Cambrex Reports Fourth Quarter And Full Year 2012 Financial Results
Date:2/6/2013

– Continuing Operations," including the Company's expectation that full year 2013 sales, excluding the impact of foreign currency, will increase between 8% and 12% versus 2012, that full year 2013 EBITDA will be between $62 and $68 million, that capital expenditures will be approximately $36 to $40 million and that depreciation will be $22 to $24 million in 2013.  These and other forward looking statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2011, captioned "Risk Factors," or otherwise described in the Company's filings with the SEC, as well as any cautionary language in the Company's Annual Report on Form 10-K for the period ended December 31, 2011, provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, governmental legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellations or delays in renewal of contracts, lack of suitable raw materials or packaging materials, and the Company's ability to receive regulatory approvals for its products, as well as risks relating to a Phase 3 supply agreeme
'/>"/>
SOURCE Cambrex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Cambrex Reports First Quarter 2012 Results
2. Cambrex To Present At Jefferies 2012 Global Healthcare Conference
3. Cambrex Announces Significant New Supply Agreement
4. Cambrex to Announce Third Quarter 2012 Financial Results on October 31, 2012
5. Cambrex Reports Third Quarter 2012 Financial Results
6. Cambrex To Announce Fourth Quarter 2012 Financial Results On February 6, 2013
7. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
8. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
11. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 4, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug ... in the upcoming Rodman & Renshaw 17 th ... in New York City .  Dr. ... a corporate overview on September 9, 2015. ...
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... Sep. 04, 2015 ... the addition of the "Pharmacovigilance (London, UK ... offering. Understanding PhV today - the ... working in Drug safety. This course ... with pharmacovigilance. New entrants as well as experienced ...
Breaking Medicine Technology:Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Pharmacovigilance Course: The Principles and Practice of Global PhV for those Working in Drug Safety (London, UK - December 7-9, 2015) 2
... N.J., March 17 Hereditary angioedema (HAE) is ... States each year. Patients with HAE suffer from ... skin, airway, and visceral organs. Left untreated, most ... per month. Chronic therapy with attenuated androgens or ...
... Surgeons to Lead Pivotal TrialANN ARBOR, Mich., March 17 ... appointed David Seth Feldman, MD/PhD, FACC, FAHA to be ... United States, studying the new, third generation DuraHeart(TM) Left ... Francis Pagani, Director of the Heart Transplant and Center ...
Cached Medicine Technology:Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies 2David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial 2David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial 3
(Date:9/4/2015)... , ... September 04, 2015 , ... According to an ... developed that changes color when subjected to an impact force that is great enough ... implemented in helmets or other sporting equipment so that coaches or officials would instantly ...
(Date:9/4/2015)... ... ... The Schmidt National Law Group filed an Essure® lawsuit against Bayer and ... Group, a leading firm in mass-tort litigation, has filed a lawsuit in the federal ... other Bayer affiliates for injuries alleged to have been caused by her Essure® contraceptive ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... Products Association (CHPA) joint meeting of its Product, Quality and Manufacturers, Dietary Supplements ... handling rules constantly evolving in the consumer goods industry, it can be difficult ...
(Date:9/4/2015)... Maui HI (PRWEB) , ... September 04, 2015 , ... ... the best ways for couples to explore, revitalize and strengthen their ‘couple-ness,’” says ... and his team at Four Seasons Resort Maui, the island’s only Forbes Five Star ...
(Date:9/4/2015)... Portland, ME (PRWEB) , ... September 04, 2015 ... ... Symposium focus on: the microbiome taking place in Hollywood, Florida October 9-10, 2015 ... ihsymposium.com/focus-event. , Speakers at the 2015 symposium are doctors and researchers at the ...
Breaking Medicine News(10 mins):Health News:New Article on Head Injury Detection Technology Highlights Implications for Head Injury Detection in Sports, says The Law Offices of Burg & Brock 2Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2
... BASEL, Switzerland, Feb. 19 Roche (SWX:,ROG.VX; ... (Nasdaq: VMSI ),today announced that Roche has ... Ventana. As of the expiration of the subsequent,offering ... had purchased a total of approximately 34,545,323 shares ...
... that uses millions of identical antibodies to boost the ... patients whose tumors recede in response to the treatment ... and rashes. In a new study, a team ... periodic infusions of such "monoclonal" antibodies to patients who ...
... shows , , MONDAY, Feb. 18 (HealthDay News) -- Statins ... to lower cholesterol levels may also cut the risk ... odds of a stroke, French researchers report. , An ... participants showed that those patients who received statins had ...
... Organizations Develop Action Plan, Announce Feline Life-Stage Guidelines ... ... Western Veterinary Conference -- The,American Association of Feline Practitioners (AAFP) today ... in Palm,Springs, Calif., with initial underwriting from Pfizer Animal Health.,Attendees were led ...
... them to kids to try to prevent fluid buildup, analysis ... significantly reduce fluid buildup in young children with inner ear ... in this regard has been a matter of conjecture, with ... and under. So, Dutch researchers did a meta-analysis of several ...
... year ago today, the,American people first learned about ... treating wounded soldiers returning,from Iraq and Afghanistan. Amid ... saw an opportunity to bolster his presidential,campaign. Days ... on former,Secretary of Defense Don Rumsfeld, saying "the ...
Cached Medicine News:Health News:Roche Completes Tender Offer for Ventana Shares 2Health News:Roche Completes Tender Offer for Ventana Shares 3Health News:Roche Completes Tender Offer for Ventana Shares 4Health News:Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer 2Health News:Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer 3Health News:Cholesterol-Lowering Drugs May Ease Irregular Heartbeat 2Health News:Cholesterol-Lowering Drugs May Ease Irregular Heartbeat 3Health News:CATalyst Summit Declared a Success: It's All About the Cat! 2Health News:CATalyst Summit Declared a Success: It's All About the Cat! 3Health News:Antibiotics Do Little for Inner Ear Infections 2Health News:Walter Reed Anniversary Exposes More McCain Double Talk 2Health News:Walter Reed Anniversary Exposes More McCain Double Talk 3
The new PERIMOUNT Magna heart valve (bioprosthesis), with its true supra-annular design, offers optimal hemodynamics and flow characteristics for treatment of aortic heart valve disease....
... background in high performance ultrasound design ... of echocardiography. Echocardiography imaging requires superior ... sensitive Doppler performance. The Terason Echo ... Teratech Architecture, delivers a compact imaging ...
... In-office. Information. In real time. The FemExam pH ... elevated vaginal fluid pH (pH >= 4.7) and ... is easy to use and delivers accurate results ... a swab containing unprocessed vaginal fluid across each ...
For the quantitative determination of human MMP-9/NGAL Complex concentrations in cell culture supernates, serum,plasma, urine and saliva....
Medicine Products: